User menu

A review of the effects of tibolone on the skeleton.

Bibliographic reference Devogelaer, Jean-Pierre. A review of the effects of tibolone on the skeleton.. In: Expert opinion on pharmacotherapy, Vol. 5, no. 4, p. 941-9 (2004)
Permanent URL http://hdl.handle.net/2078.1/9812
  1. ANONYMOUS, Diagnosis, prophylaxis, and treatment of osteoporosis. iAm. Med. i, 94, 646 (1993)
  2. Cummings Steven R, Melton L Joseph, Epidemiology and outcomes of osteoporotic fractures, 10.1016/s0140-6736(02)08657-9
  3. WORLD HEALTH ORGANIZATION, Report of a WHO Study Group. iWorld Health Organ. Tech. Rep. Ser. i, 843, 1 (1994)
  4. DEVOGELAER JP, Rheum. i, 11, 539 (1997)
  5. MELTON LJ, Res. i, 7, 1005 (1992)
  6. de Deuxchaisnes Charles Nagant, Devogelaer Jean-Pierre, Increase in the incidence of hip fractures and of the ratio of trochanteric to cervical hip fractures in Belgium, 10.1007/bf02556335
  7. CRANNEY A, GRIFFITH L iet al.: i IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. iEndocr. Rev i, 23, 570 (2002)
  8. MEUNIER PJ, SEEMAN E iet al.: i The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. iN Engl. Med. i, 350, 459 (2004)
  9. KLOOSTERBOER HJ, iSteroid Biochem. i, 76, 231 (2001)
  10. DE GOOYER ME, iSteroids i, 68, 21 (2003)
  11. ALBERTAZZI P, iMaturitas i, 30, 295 (1998)
  12. DAVIS SR, iMenopause i, 9, 162 (2002)
  13. CHLEBOWSKI RT, iJAMA i, 289, 3243 (2003)
  14. LI CI, PORTER PL iet al.: i Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. iJAMA i, 289, 3254 (2003)
  15. Breast cancer and hormone-replacement therapy in the Million Women Study, 10.1016/s0140-6736(03)14065-2
  16. MUECK AO, iArch. Cynecol °Enter i, 267, 139 (2003)
  17. ZANDBERG P PETERS JLM, iMenopause i, 8, 96 (2001)
  18. FARISH E, iMaturitas i, 20, 215 (1995)
  19. HAENGGI W, iCynecol Endocrinol i, 13, 202 (1999)
  20. Ederveen A. G. H., Kloosterboer H. J., Tibolone Exerts Its Protective Effect on Trabecular Bone Loss Through the Estrogen Receptor, 10.1359/jbmr.2001.16.9.1651
  21. LINDSAY R, iBr. Med. J. i, 280, 1207 (1980)
  22. GEUSENS P, iMaturitas i, 13, 155 (1991)
  23. BJARNASON NH, iBone i, 20, 151 (1997)
  24. BERNING B, iBone i, 19, 395 (1996)
  25. STUDD J, i°Enter Cynecol. i, 92, 574 (1998)
  26. PAVLOV PW, iCynecol Endocrinol i, 13, 230 (1999)
  27. Gallagher J. C., Baylink David J., Freeman Ruth, McClung Michael, Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies, 10.1210/jcem.86.10.7937
  28. LYRITIS GP, BASDEKIS K iet al.: i Prevention of post-oophorectomy bone loss with tibolone. iMaturitas i, 22, 247 (1995)
  29. BEARDSWORTH SA, iBr. J. Obstet. Cynaecol. i, 106, 678 (1999)
  30. MILNER M, iMenopause i, 7, 327 (2000)
  31. PRELEVIC GM, iCynecol Endocrinol i, 10, 413 (1996)
  32. Lippuner Kurt, Haenggi Willy, Birkhaeuser Martin H., Casez Jean-Paul, Jaeger Philippe, Prevention of Postmenopausal Bone Loss Using Tibolone or Conventional Peroral or Transdermal Hormone Replacement Therapy with 17β-Estradiol and Dydrogesterone, 10.1359/jbmr.1997.12.5.806
  33. CASTELO-BRANCO C, iMaturitas i, 34, 161 (2000)
  34. Roux C., Pelissier C., Fechtenbaum J., Loiseau-Peres S., Benhamou C. L., Randomized, Double-masked, 2-year Comparison of Tibolone with 17β-Estradiol and Norethindrone Acetate in Preventing Postmenopausal Bone Loss, 10.1007/s001980200021
  35. GREENSPAN SL, A randomized, double-blind, placebo-controlled trial. iAnn. Intern. Med. i, 137, 875 (2002)
  36. BERNING B, iMaturitas i, 31, 151 (1999)
  37. Felson David T., Zhang Yuqing, Hannan Marian T., Kiel Douglas P., Wilson Peter, Anderson Jennifer J., The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women, 10.1056/nejm199310143291601
  38. RYMER J, iOsteoporos. i, 4, 314 (1994)
  39. RYMER J, 5 mg daily on postmenopausal bone loss. iOsteoporos Int. i, 12, 478 (2001)
  40. HUBER J, BERGLUND L iet al.: i Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. iBr. °Enter Cynaecol. i, 109, 886 (2002)
  41. Valdivia Isabel, Ortega Dulia, Mammographic Density in Postmenopausal Women Treated with Tibolone, Estriol or Conventional Hormone Replacement Therapy : , 10.2165/00044011-200020020-00005
  42. CHRISTODOULAKOS GE, iMenopause i, 9, 110 (2002)
  43. REGINSTER J-Y, AGNUSDEI D, GENNARI C, KICOVIC, iCynecol Endocrinol i, 13, 361 (1999)
  44. BROOKE-WAVELL K, iMaturitas i, 35, 229 (2000)